Cartesian Therapeutics Stock Market Value
| RNAC Stock | 6.98 0.30 4.12% |
| Symbol | Cartesian |
Will Stock sector continue expanding? Could Cartesian diversify its offerings? Factors like these will boost the valuation of Cartesian Therapeutics. Anticipated expansion of Cartesian directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cartesian Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Cartesian Therapeutics is measured differently than its book value, which is the value of Cartesian that is recorded on the company's balance sheet. Investors also form their own opinion of Cartesian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cartesian Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Cartesian Therapeutics' market value can be influenced by many factors that don't directly affect Cartesian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Cartesian Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cartesian Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Cartesian Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cartesian Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cartesian Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cartesian Therapeutics.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Cartesian Therapeutics on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Cartesian Therapeutics or generate 0.0% return on investment in Cartesian Therapeutics over 90 days. Cartesian Therapeutics is related to or competes with Inventiva, Nautilus Biotechnology, Orchestra BioMed, Mediwound, Aardvark Therapeutics, Fennec Pharmaceuticals, and Avalo Therapeutics. More
Cartesian Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cartesian Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cartesian Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 28.9 | |||
| Value At Risk | (8.01) | |||
| Potential Upside | 7.26 |
Cartesian Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cartesian Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cartesian Therapeutics' standard deviation. In reality, there are many statistical measures that can use Cartesian Therapeutics historical prices to predict the future Cartesian Therapeutics' volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | (0.52) |
Cartesian Therapeutics January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.51) | |||
| Mean Deviation | 3.63 | |||
| Coefficient Of Variation | (3,599) | |||
| Standard Deviation | 4.96 | |||
| Variance | 24.63 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | (0.52) | |||
| Maximum Drawdown | 28.9 | |||
| Value At Risk | (8.01) | |||
| Potential Upside | 7.26 | |||
| Skewness | 0.5118 | |||
| Kurtosis | 1.91 |
Cartesian Therapeutics Backtested Returns
Cartesian Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0278, which signifies that the company had a -0.0278 % return per unit of risk over the last 3 months. Cartesian Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Cartesian Therapeutics' Standard Deviation of 4.96, risk adjusted performance of (0.01), and Mean Deviation of 3.63 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.28, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cartesian Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cartesian Therapeutics is expected to be smaller as well. At this point, Cartesian Therapeutics has a negative expected return of -0.14%. Please make sure to confirm Cartesian Therapeutics' daily balance of power, and the relationship between the skewness and day typical price , to decide if Cartesian Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.12 |
Insignificant predictability
Cartesian Therapeutics has insignificant predictability. Overlapping area represents the amount of predictability between Cartesian Therapeutics time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cartesian Therapeutics price movement. The serial correlation of 0.12 indicates that less than 12.0% of current Cartesian Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.12 | |
| Spearman Rank Test | -0.48 | |
| Residual Average | 0.0 | |
| Price Variance | 0.3 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VTI | Vanguard Total Stock | |
| RIOT | Riot Blockchain | |
| TSLA | Tesla Inc |
Check out Cartesian Therapeutics Correlation, Cartesian Therapeutics Volatility and Cartesian Therapeutics Performance module to complement your research on Cartesian Therapeutics. For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Cartesian Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.